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Abstract
Synthetic peptide-based vaccine prototypes are the future potential vaccination. 
Antigens, which belong to minimal microbial component and produce antibodies 
such as peptides and polysaccharides, can promote long-term protection against 
pathogens that can cause infectious diseases. Production of peptides becomes sim-
ple with solid phase peptide synthesis and microwave-assisted solid phase peptide 
synthesis using automatic synthesizers. The use of synthetic peptides was approved 
by the health authorities for vaccine design. Peptides are themselves very weak 
immunogens and need adjuvants to provide an effective autoimmune response. 
For this reason, peptide antigens are conjugated with biopolymers and loaded with 
nanoparticles. The toxicity of vaccine prototypes is evaluated in cell culture, and 
non-toxic prototypes are selected for vaccinating experimental animals. The most 
effective peptide-based vaccine prototype is determined as the one with the highest 
antibody level. The goal of this book chapter is to illustrate the use of peptides vac-
cine systems and present their opportunities with their future development.
Keywords: biopolymers, nanoparticle systems, solid phase peptide synthesis (SPPS), 
synthetic peptide, peptide vaccine prototype
1. Introduction
The goal of this chapter is to review the importance of synthetic peptide-based 
vaccination, providing a brief knowledge about their new generation prototypes. In 
the first stage, relation to immunity and peptide vaccine with importance of using 
biopolymers was given under the title of solid-phase peptide synthesis including 
microwave system. After that, this review was focused on the established methods 
for peptide loaded nanoparticles or conjugated biopolymers preparation of peptide-
based vaccine prototypes and nanotechnological particles as delivery system 
with touching on different methods. In addition, the impact of Contemporary 
Advancements in Peptide Based Vaccine like Liposome Based Subunit Vaccines was 
explained. In the last part, peptide-based vaccine prototypes studies in vivo and 
in vitro were given with their future perspective and development.
2. Peptide vaccines prototype and immunity
All vaccines generally are developed by using live or attenuated microorganisms. 
However, the use of whole microorganisms, their components or the biological 
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process for vaccine production has many weaknesses and a variety of approaches 
for synthetic peptide vaccination remain under investigation for the infectious 
diseases [1]. Peptides play an important role in a biological process, including the 
stimulate the immune response [2].
Peptide-based vaccination is an immunotherapy where a peptide is applied often 
with the use of an immunoadjuvant (nanoparticle or biopolymers) to stimulate 
T-cell and sometimes B-cell immunity. Peptide-based vaccinations are present in 
major histocompatibility complexes (MHC) the ultimate target for T cells in infec-
tion recognition and infection immune responses [3, 4]. Sometimes peptide-based 
vaccines play a role to stimulate innate and adaptive immunity both (Figure 1) 
and peptides are immunogen components of peptide-based vaccine and memory 
responses of peptide is weak in immune responses [1] without the biopolymer or 
nanoparticle system.
When producing a new generation of synthetic peptide vaccines, components 
of the pathogenic pathogen of interest are generally used. These components are 
linear peptides and produced by solid phase peptide synthesis (SPPS) method with 
high efficiency and purity [5–9]. When peptides are used in combination with a 
vaccine system, if they are used without a drug delivery system, there are risks of 
degradation by protease enzymes that break down proteins and phagocytosis by 
immune system cells such as antibodies [10]. In addition, drug delivery systems 
should be preferred as nanoparticles and biopolymers. A higher immune response 
Figure 1. 
Cellular representation of immune cells after vaccination [1].
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and to protect peptides from harmful effects of degrading enzymes and aggressive 
antibodies, it is generally necessary to use nanosystems such as protein, biopolymer 
conjugations or nanoparticles (NPs). Peptide delivery systems based on nanopar-
ticles are developing more and more for the development of peptide-based vaccines. 
Especially, biodegradable polymers offer very popular and patented vaccines [11]. 
For instance, poly(amino acid) and polylactic acid (PLA) are used for NPs and 
when antigenic peptides are encapsulated by them in order to vaccinate mice can 
provide significantly higher levels of total the antibodies like immunoglobulins 
(IgGs); IgG, IgG1, IgG2. This means they can able to stimulate humoral immune 
responses and also CD4+ and CD8+, T and B cell activation and for the cellular 
immune responses; interferon γ (IFNγ) which induce Ig class switching to IgG2a 
[12–14]. In another study, Murine model was used in an immunization study. An 
antigen of Hepatitis B disease loaded on Poly (lactic-co-glycolic acid) (PLGA) 
NPs (300 nm) provided better immune responses compared to the antigen alone. 
Immunization with PLA NPs (200–600 nm) can also provide higher levels of IFNγ 
production related to a Th1 response. In contrast, immunization of PLA micropar-
ticles (2–8 μm) promoted IL-4 secretion due to Th2 response [15]. Both PLGA NPs 
and liposomes are phagocytosed efficiently by cells to localize intracellular localiza-
tions and produce an immune response [16, 17]. Carbon NPs are promising in oral 
vaccine administration for the use of synthetic peptides [18].
Different approaches are available to develop synthetic peptide-based vaccines, 
using metal ions in combination with peptide sequences. In particular, the inves-
tigation of the complex formation biopolymer by peptide in the presence of metal 
ions contributes greatly to the technological development of peptide-based vaccine 
prototypes [19]. The contact of the peptides with the polyelectrolyte (PE) is found 
at the interface. Solubility of polyplexes and complexes with NPs and peptides; 
it depends on the structure of the peptides (such as hydrophilic and lipophilic) 
and correlates with the isoelectric points in this system. Metal ions such as copper 
(Cu+2) generally promote two effects: (1) conjugation of polyelectrolyte to peptide 
molecules and (2) aggregation of polyplex particles in the intermolecular region. 
Some of these polyplexes exhibit strong immunogenicity and provide a high level of 
immunological protection for peptide vaccine prototypes, making them more effi-
cient, but the solubility, composition and stability of these polycomplexes depend 
on pH, metal/PE and protein/PE ratios. These systems are based on conjugation of 
PE and antigen molecules with covalent bonds to NPs or biopolymers, which induce 
an immune response to the immunizing agent. The hydrophobic interactions in 
such a complex create an adjuvant effect for prototyping technology in vaccination. 
[19–22]. In the studies on the development of peptide vaccine prototypes previously 
made by our study group, it was observed that the purification of characterization 
of binding of synthetic peptides to various adjuvants and subsequent high immune 
response was obtained in BALB/c mice from experimental animals [23].
3. Solid-phase peptide synthesis (SPPS)
A historical overview of peptide chemistry from T. Curtius (who achieved the 
first synthesis of peptide in 1882) and Fischer (who synthesized the first dipeptide 
in 1901) to M. Bergmann and L. Zervas is first in presenting the Solid-Phase peptide 
synthesis. Next, the fundamentals of peptide synthesis with a focus on SPPS by 
R. B. Merrifeld are described. Although the peptides can be synthesized in three 
methods: in a solution medium, on a solid support, or as a combination of the 
solid and the solution synthesis, this chapter emphasizes an overview of peptide 
synthesis giving importance on SPPS. Currently, most of the peptides for research, 
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vaccination or therapeutic drugs for cancer and brain diseases are synthesized by 
SPPS methods. Successful peptide synthesis depends on the appropriate selection of 
suitable resins, linkers, amino acid derivatives and coupling reagents, as well as the 
side chain (de) protection and cleavage conditions, and the correct synthesis of the 
assay. In the SPPS method, the solid support is attached at the end of the first amino 
acid-COOH at the carboxyl end a polymeric support insoluble in the newly formed 
peptide chain is referred to as resin. A covalent binding step that binds the resin is 
important for the reaction [24]. The peptides may be gradually joined between the 
C and N terminus using N-protected amino acids. The Nα protecting group (Boc) 
is unstable in the presence of intermediate acid (trifluoroacetic acid; TFA), the side 
chain protecting benzyl (Bzl) based groups and the peptide/resin linkage are stable 
in the presence of intermediate acid and are variable in the presence of strong acid 
(HF). Fmoc group is important for solid-phase applications. Fmoc-based strategies 
are also available, and hydroxymethylphenoxy-based binders are used to add pep-
tide to the resin with t-butyl (tBu) based side chain protection [25]. The solid phase 
peptide synthesis method consists of three basic steps. According to this, deprotec-
tion of the carboxyl group activation and peptide bond formation (Coupling). 
Following this procedure, the final deprotection of the last added amino acid is 
removed and the N- terminal is released. Cleavage and deprotection of the resin-
bound peptide from the solid support [26].
The stepwise representation of solid phase peptide synthesis is illustrated in 
Figure 2. The starting amino acid masked by a non-persistent protecting group at 
the N-α terminus is loaded from the C-terminus to the resin. A semi-permanent 
protection group can also be used to mask the side chain if necessary (Figure 3, 
Step 1). The synthesis of the peptide, repeated deprotection of the N-α-transient 
protecting group, and binding of the next protected amino acid (Figure 3, Step 3). 
Figure 2. 
The antigens and immunomodulators that can be used for inclusion in liposomes; it is shown in different 
strategies depending on the target and structure of the molecule [28].
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After the last amino acid is loaded (Figure 3, Step 4), the peptide is separated from 
the resin support and the Fmoc or Boc groups are removed [25].
The development of microwave-assisted solid-phase peptide synthesis has 
been developed by the synthesis of linear and complex peptide sequences and long 
Figure 3. 
Stepwise representation of solid phase peptide synthesis [25].
Synthetic cycle Reagents Time & conditions
Deprotections Trifluoroacetic acid (Boc) and 20% piperidine in DMF 
(Fmoc)
1–5 min (70°C  
Fmoc and Boc)
Couplings Amino acids, HBTU/HATU/HOBt/HOAt/DIC, DIPEA 5–15 min
50–70°C
Table 1. 
Synthetic cycle and important reagents with time and conditions in microwave-assisted SPPS [27].
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peptide sequences in a shorter time and high throughput. Time and temperature 
conditions, reagents and synthesis cycle for microwave assisted SPPS with using 
Boc or Fmoc are represented below in Table 1. The disadvantage of this technique 
could be the cost of resin (the binding procedure of the first binding amino acid to 
the resin in peptide synthesis can requires different and complex processes) and 
equipment [27, 29].
4. Peptide-based vaccine for nanotechnological prototypes
Synthetic peptides alone are not sufficient to develop vaccine prototypes because 
they cannot stimulate the cellular and humoral protection system sufficiently. So, 
different adjuvant systems are formed by conjugating the peptides biopolymers 
or loading them into NPs, resulting in a high immune response [30]. The use of 
peptide-polymer complexes and peptide loaded nanoparticles are the best way for 
the developing the peptide-based vaccine prototypes.
4.1 Type of nanoparticles
The binding of the antigenic peptides with the water-soluble polymer has 
multiple effects. Some of those are as follows:
• to provide modification of peptides,
• to increase the water solubility of those with hydrophobic properties,
• to raise regional impact,
• to increase immunogenic effects and immunoreactivity, and
• to be more effective in the living organism [31].
NPs are spherical polymeric carriers. The particles that are below 1000 nano-
meters (nm) are called nanoparticles. These particles with superior properties are 
used in many fields such as electricity, electronics, biotechnology, automotive, 
medical. NPs are morphologically and physicochemically influenced by the physical 
and chemical properties of the starting material used. The nanoparticles used as 
polymeric carriers are solid colloidal structure. The active substance can be encap-
sulated, absorbed or dissolved in the particle. Polysaccharides, polyanhydride, 
polycaprolactone, polyacrylic acid and polylactic-co-glycolic acid is also used for 
producing an effective nanoparticles and produce a co-polymer system such as 
poly(ethylene glycol) (PEG)-Nps and poly(ethylene glycol)-poly(ε-caprolactone) 
copolymers (PEG-PCL) copolymers. The copolymers of N-vinyl-2-pyrrolidone with 
acrylic acid (P(VP-co-AA)), PLGA, NPs loaded with the antigenic peptide can be 
used for future vaccine prototypes [32]. PLGA NPs is approved by U.S. Food and 
Drug Administration (FDA) and using for peptide carrier in vivo because of strong 
immune response [33].









6. PEG-poly (amino acids)
7. Stimuli-sensitive polymeric micelles
8. Endogenous stimuli-sensitive polymeric micelles
9. pH-sensitive polymeric micelles
10. Reduction sensitive polymeric micelles
11. Thermo-sensitive polymeric micelles
12. Exogenous stimuli-sensitive polymeric micelles
13. Light-sensitive polymeric micelles
14. Magnetic field-sensitive polymeric micelles
15. Ultra-sound sensitive polymeric micelles
16. Margination of micro/NPs: Requirement for optimum drug delivery
5.  Established methods for peptide loaded NPs or conjugated 
biopolymers preparation
We have mentioned that the peptides alone cannot produce an adequate immune 
response and also have poor stability with the internalization problem while cross-
ing cell membranes. To solve all these limitations, peptides are loaded nanoparticle 
systems or conjugated biopolymers. Biopolymers are generally nontoxic products 
are generally preferred for producing continuously release systems with long term 
effect [34]. Here, the applicable and most common strategies for the synthesis of 
peptide-based NPs and encapsulation or conjugated methods of biopolymers are 
shown.
5.1 Emulsification-solvent evaporation method
The emulsion solvent evaporation technique is known as the most successful 
and useful method in the preparation of peptide loaded NPs and this technique 
is studied under two groups as single and double emulsion solvent evaporation 
methods [35].
5.2 Conjugation methods
Conjugation is a technique for achieving peptide and biopolymer complexes. 
The covalently linked peptide biopolymer conjugates can be linked using the 
water-soluble carbodiimide method as a cross-linker and synthesis with microwave 
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energy methods [36]. Peptides conjugates biopolymers can be synthesized in 
organic media using microwave energy. Also, there are another methods, including 
complex formation of biopolymers and peptides and electrostatic complex forma-
tion and metal coordination via ion coordination [35]. Specific antibody titers were 
observed in mouse experiments against peptides containing polymeric conjugates 
and complexes. The molecular weights of these conjugates are also very important. 
Biopolymer conjugation is crucial to obtain a high immune response to antigens at 
low molecular weights [37–39].
5.3 Nanoprecipitation
Nanoprecipitation is the most strategic method for the preparing of vaccine   
prototypes. Reducing the pH is very important to stabilization of system. Also, 
salt  concentration under the solubility conditions is another important thing for 
the  encapsulation method [70]. If the experiments cannot move on then adding 
a non-solvent phase in the quality of the solvent technique in which the parent 
compound of the NPs is dissolved can help [40]. Nanoprecipitation is frequently 
used in encapsulation of peptides. A pH-controlled precipitation rather than a 
non-solvent precipitation is a more preferred approach for passing the polymer to a 
non-dissolved phase with a simple pH change in the medium. For NPs or biopoly-
mers prepared by nanoprecipitation, these solvents are known as the organic phase 
of acetone and ethanol [41].
5.4 Encapsulation of peptide
Encapsulation is carried out simultaneously by synthesizing NPs and biopoly-
mers in all of the methods mentioned the encapsulation method for peptides should 
be selected based on the hydrophobic or hydrophilic facilities of peptide. Using of 
peptide encapsulation is important because of
• peptide release controlling,
• modeling of targeted delivery systems,
• mask unfavorable organoleptic properties (taste, odor, color),
• protection of peptide from immune attacks and enzyme degradation,
• insurance of bioconjugate molecules stability,
• decrease toxicity, and
• design of new dosage forms [42].
5.5 Peptide characterization
After purification of the peptides, they are commonly characterized by liquid 
chromatography-electrospray ionization-mass spectrometry (LS-ESI-MS), fluo-
rescence spectroscopy and possible three-dimensional structures of the synthetic 
peptide (PEP-FOLD) server. It has validation since the chromatographic method 
has positive properties in terms of linearity, accuracy, precision and repeatability. 
Synthetic peptide vaccines are immunogens that can be used when creating vaccine 
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prototypes, especially because of their lipophilic structure (which also allows cell 
permeability to pass easily) [43]. Methods such as Fourier transform infrared 
(FT-IR) and nuclear magnetic resonance (1H- and 31P-NMR) are frequently used to 
visualize the physical structure of the copolymer and peptide biopolymer conju-
gates and to perform characterization studies. The conjugation of molecular weights 
is measured via size-exclusion chromatography (SEC) [44].
5.6 Characterization of peptide vaccine prototype
Ultraviolet (UV) and FT-IR Spectrophotometers and ZetaSizer are used for 
studying the nanoparticles and Scanning Electron Microscope (SEM) is used for 
morphological examination of Polymers or bioconjugate [45].
5.7 Toxicity studies
Peptide-based vaccine prototypes need to be tested in a cell culture medium to 
be feasible because they may have physiological, biological and chemical effects, 
causing cytotoxicity. The method used to investigate the cytotoxic profiles of 
peptide-based vaccines is also called in vitro cytotoxicity assays or cell culture-based 
measurement methods [46, 47]. Tetrazolium salts are compounds used in cell lines 
to measure the metabolic pathways of cells of microbial origin. Tetrazolium salts 
are the heterocyclic organic structure of these compounds and their reduction 
to colorless or weak colored aqueous solutions known as formazans has been the 
basis of their use as vital dyes in redox chemistry, biological and chemical applica-
tions [46, 47]. The tetrazolium ring can only be broken by active mitochondria, so 
viable cells and dead cells can be distinguished by discoloration. The fact that this 
change can be made only by living cells in vitro has made tetrazolium compounds 
a highly biologically important to measure toxicity of peptide-based vaccine 
formulas. The mechanism of toxicity assays, such as 3-(4,5-dimethylthiazolyl)-2,5 
diphenyltetrazolium bromide (MTT) [19], 3-(4,5-dimethylthiazol-2yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), 2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-5[(phenylamino)carbonyl]-2H-tetrazolium 
hydroxide (XTT), sodium 5-(2,4-disulfophenyl)-2-(4-iodophenyl)-3-(4-
nitrophenyl)-2Htetrazolium inner salt (WST), 5-methyl-phenazinium methyl 
sulfate(PMS), 5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-2-thiazo-
lyl)-2-(4-  sulfophenyl)-2H-tetrazolium inner salt; (MTS) are used [49, 50] and in 
our studies, we generally use MTT analysis. For example, our technological vaccine 
prototype example is Zika peptide loaded PLGA nanoparticles which were deter-
mined on ECV304 human epithelial cells via MTT assay, which is the cytotoxicity 
test, was performed to determine the cytotoxic effects of the peptide, peptide 
loaded NPs [45]. The importance of toxicity studies is to determine the non-toxic 
vaccine prototype and to switch to in vivo animal studies.
5.8 Contemporary advancements in peptide based vaccine
5.8.1 Liposome based subunit vaccine
Live attenuated vaccine is highly immunogenic and considered as well-tolerant 
for healthy individuals. However, live attenuated vaccine should not be admin-
istered to immunocompromised individual as it would cause systemic infection. 
An alternative vaccine technology, subunit vaccine, is safer and more suitable for 
immunocompromised individual. It uses fragment of a pathogen (antigen) to trig-
ger an immune response and stimulate immunity against the pathogen. However, 
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subunit vaccine has low immunogenicity and often combined with adjuvants to 
induce protective immunity. The adjuvants are capable to enhance vaccine effec-
tiveness and stimulate immune responses [28].
Human alphaherpesvirus 3 (HHV-3) is known as Varicella-zoster virus 
(VZV), which is the causative agent of varicella (chicken pox) and herpes 
zoster (shingles). In 1978, the first commercial Varicella-zoster immune 
globulin, Vzig™ (Massachusetts Public Health Biologic Laboratories, Boston, 
Massachusetts) became available. However, the supply was removed from 
the U.S. market in 2006. The alternative preparation, Varizig® (Cangene 
Corporation, Winnipeg, Canada) was licensed by FDA in 2012 and has shown to 
be comparable to Vzig™ [Saol Therapeutics Inc. 2012]. Varizig® is supplied as a 
sterile solution containing human Varicella-zoster immune globulin (IgG) which 
showed for post-exposure prophylaxis in high-risk patients [51].
Zostavax® is the vaccine licensed for herpes zoster prevention in individuals 
above the age of 50. It is a lyophilized preparation which is given as subcutaneous 
injection [52]. A non-replicating liposome-based subunit vaccine (HZ/su) is the 
new development for zoster prevention. The HZ/su is a non-live recombinant VZV 
glycoproteins E with the adjuvant ASO1B [53]. A randomized placebo-controlled 
study has shown that HU/su poses age-independent defense against HZ and has 
better efficacy compared to Zostavax® in reducing the risk of HZ for immunocom-
promised adults with the age above 50. Unlike HZ/su, Zostavax® lose efficacy as 
age increase [54]. HZ/su vaccine is not yet approved by FDA.
Figure 4. 
General features of virus-like particle [48].
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Liposomes are nano-carriers and they are useful in delivering vaccine antigen by 
forming liposome-based vaccine delivery systems. It is advantageous over other car-
riers due to its biocompatibility, non-toxic and biodegradable features [55]. Besides, 
liposomes can be customized to achieve desired immune profiles by optimizing their 
composition, antigen-loading strategies and the use of adjuvants system [28, 56].
5.8.2 Virus-like particle
Eculizumab (Soliris®) is a humanized monoclonal antibody (mAb) which 
function as a terminal complement inhibitor [57]. It was the first therapeutic agent 
approved by the FDA for atypical hemolytic uremic syndrome (aHUS) and parox-
ysmal nocturnal hemoglobinuria (PNH)-associated with thrombotic microangiopa-
thy (TMA) in 2007 and 2011 respectively [58]. Soliris® (Alexion Pharmaceuticals, 
New Haven, Connecticut, USA) is in the form of sterile solution for i.v. injection. 
Eculizumab increases the patient’s susceptibility to meningococcal infection 
(Neisseria meningitidis), all patients must be vaccinated against meningococcal 
infections prior to or at the time of initiating Eculizumab.
Virus-like particles (VLPs) is one of the alternative types of nanoparticles deliv-
ery system [59]. A recent research has shown that the development of autologous 
C5 vaccine in nanoparticle form is able to elicit strong humoral responses [60]. A 
peptide epitope (PADRE peptide) in the C5 vaccine is used to create a recombinant 
virus-like particles (VLPs). It showed a reduction in hemolytic activity and protect 
the mice from complement-mediated intravascular hemolysis [60]. Based on the 
study’s result, it is showed that the recombinant VLPs could be used as an alterna-
tive or supplement for Eculizumab.
VLPs is known as an emerging class of targeted delivery vehicles with potential 
of overcoming the limitations of other nanoparticles [48]. VLPs is a potential 
delivery system due to their immunogenic nature, well-defined structure, ability to 
present a wide variety of potential epitopes, and ease of production [60]. They lack 
natural genome thus it is non-infectious. Besides, it can turn as self-adjuvant which 
is proficient in breaking the immune tolerance.
One of the limitations of VLPs are phagocyte-mediated clearance [59]. Besides, 
a recent study showed that ellipsoid nanoparticles can extravasate from the blood 
vessel more effectively than spherical nanoparticles. Meanwhile, the ellipsoid shape 
is possible for conventional polymeric NPs, but is not feasible for icosahedral VLPs. 
However, this limitation can be overcome through the modification of VLP surface 
by adding a variety of useful ligands [61]. VLPs may be able to efficiently extrava-
sate from the vasculature of the blood vessels by showing multiple ligands with high 
affinity for the tight connections between endothelial cells [59].
6.  Importance in vitro and in vivo experiments using peptide-based 
vaccine prototypes
After forming a synthetic vaccine prototype, the cytotoxicity of the bioconju-
gate of the peptides and biopolymers is first determined (generally we use MTT 
analysis). After the apoptotic effect of the prototype on living cells is measured by 
flow cytometric detection, the vaccine prototype with the most viable cell number 
should be selected for further study [62]. After all these methods, immunization is 
the next step. We immunize BALB/c mice with each one of the peptides biopolymer 
conjugates or peptides loaded nanoparticles following conventional immuniza-
tion protocol. The goal is to identify the most antigenic vaccine prototype. The 
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antibodies are measured in blood (for humeral response such as; T and B lym-
phocytes, IgGs) or splenic (cellular response like ILs and IFNs) samples from the 
immunized BALB/c mice via the indirect enzyme-linked immunosorbent assay 
(ELISA) to determinate the highest antibody level. Thus, the most suitable peptide-
based vaccine prototypes will be identified for future clinical phase studies. In 
brief, cell culture and toxicity studies are important before the analyses the effect of 
vaccine prototype in vivo [62].
7. Current situation and future perspective
Peptides can affect important brain regions that are essential for life-sustaining 
functions. There are studies about Peptide drug and Peptide-Polymer Vaccines 
and drugs using for brain disorders. In this future perspective we will explain 
the using of peptides in common brain disorders such as Alzheimer Disease, 
Parkinson Disease (PD), Multiple Sclerosis. In a study using an interference-
inducing peptide (TAT-DATNT) to elute a protein complex consisting of inter-
action between DAT and the dopamine D2 receptor (D2R), it was determined 
that locomotor behaviors were induced in Sprague–Dawley (SD) rats. This 
peptide can provide potential therapy for regulating the activity of DAT and 
dopaminergic neurotransmission of Attention Hyperactivity Deficit Disorder 
(ADHD) therapies [63]. Alpha Synuclein (A-syn) aggregate is very important 
for the PD. Against of this aggregate, an immunogenic peptide the sequence 
of CGGVDPDN [64] is developed with solid phase peptide synthesis method 
as a vaccine in PD. Peptides can also be neuroprotection for the PD. TFP5 pep-
tide, FITCGGGKEAFWDRCLSVINLMSSKMLQINAYARAARRAARR; TP5 
peptide, KEAFWDRCLSVINLMSSKMLQINAYARAARRAARR; SCP peptide, 
FITCGGGGGGFWDRCLSGKGKMSSKGGGINAYARAARRAARR are reduction in 
neuroinflammation and apoptosis. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine) is a neurotoxin drug of MPP+, which causes permanent symptoms 
of PD  by destroying dopaminergic neurons in the substantia nigra of the brain 
for mouse modeling [65]. PD01A is a Phase 1 epitope vaccine in experimental — a 
synthetic a-syn mimicking peptide-polymer based on a-syn aggregate by induc-
ing an immune response that generates antibodies specifically against it [66]. In 
general, vaccines are developed according to the T cell response, but a peptide 
epitope with a three-celled peptide epitope with a three-cell universal peptide such 
as Syn85-99 (AGSIAAATGFVKKDD), α-Syn109-126 (QEGILEDMPVDPDNEAYE), 
α-Syn126-140 (EMPSEEGYQDYEPEA) and P30 (FNNFTVSFWLRVPKVSASHLE) 
epitope vaccines comprising three peptide-based epitope vaccines comprising 
different α-Syn peptides, but consisting of different B cell epitopes as follows, are 
noted for their high immunogenicity [67]. So peptides can have different immune 
cell response in brain disorders. Peptides can also protect cell biological agents such 
as microtubules activity. This is very important for cell stability while the diseases 
are seen in the cells. The dysregulation of ADNP / ADNP2 expression in the rel-
evant brain tissue and animal model may improve the prognosis of schizophrenia 
because these genes are responsible for the regulation of interacting microtubules. 
The microtubule-interacting drug candidate, NAP (davunetide) is a small peptide 
and belong to activity-dependent neuroprotective protein (ADNP) which contains 
a small peptide motif, NAPVSIPQ sequence that provides potent neuroprotection 
for tau pathology, neuronal cell death as well as social and cognitive dysfunctions 
[68]. Especially in Amyloid beta pathology, DAEFRHDSGY peptide, Wang et al. 
synthesized peptide immunogens, A1-14 peptide immunogens for UBITh® AD 
immunotherapeutic vaccine by using automated SPPS for the Alzheimer Disease. 
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Wang’s group has developed a synthetic peptide vaccine prototype for the preven-
tion and treatment of AD and is conducting phase II clinical trials. The occurrence 
of Alzheimer’s disease constitutes a strong immune response to Amyloid Beta (Ab) 
Plaques; UB-311 was constructed with two synthetic Ab1-14 targeting peptides (B 
cell epitopes), each bound to different helper T cell peptide epitopes and formulated 
in a Th2 delivery system [69].
8. Conclusion
Consequently, this chapter provides a brief manual for anyone in the fields of 
solid-phase peptide synthesis, peptide vaccines, Nanotechnological importance for 
effective vaccine prototypes, and their future perspective for other diseases such as 
brain disorders.
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